Abstract | BACKGROUND: AIM: METHODS: This was a 3-year retrospective study. Twenty-seven patients were assessed with a median follow-up of 23 months. Thirteen patients were switched from subcutaneous octreotide and 14 patients were octreotide naive. All patients showed avid uptake on indium-111 octreotide imaging. RESULTS: Ten of the 13 patients previously on subcutaneous octreotide and 13 of the 14 patients who were octreotide naive had good symptom control on Sandostatin LAR. Over the period of follow-up, many patients showed progression of their tumour and required additional therapies. Patients expressed a preference for monthly intramuscular Sandostatin LAR as opposed to daily subcutaneous injections of octreotide. Although Sandostatin LAR was difficult to administer in certain instances, overall it was well tolerated. CONCLUSIONS:
|
Authors | J Garland, J R Buscombe, C Bouvier, P Bouloux, M H Chapman, A C Chow, N Reynolds, M E Caplin |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 17
Issue 3
Pg. 437-44
(Feb 2003)
ISSN: 0269-2813 [Print] England |
PMID | 12562458
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Delayed-Action Preparations
- Octreotide
|
Topics |
- Adult
- Aged
- Antineoplastic Agents, Hormonal
(administration & dosage)
- Delayed-Action Preparations
- Female
- Humans
- Injections, Intramuscular
- Male
- Malignant Carcinoid Syndrome
(drug therapy)
- Middle Aged
- Octreotide
(administration & dosage)
- Retrospective Studies
- Treatment Outcome
|